Hydroxyprogesterone caproate powder video
Hydroxyprogesterone caproate powder basic Characters
|Name:||Hydroxyprogesterone caproate powder|
Hydroxyprogesterone caproate powder
Chemical Names:Hydroxyprogesterone caproate powder
Brand Names: Hydroxyprogesterone caproate(OHPC) powder, Delalutin powder, Proluton powder, 630-56-8
Hydroxyprogesterone caproate powder Usage
THIS INFORMATION IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND SHOULD NOT BE USED AS A SOURCE FOR MAKING PRESCRIBING OR OTHER MEDICAL DETERMINATIONS.
1) For preterm delivery prophylaxis in females with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Intramuscular dosage (single and multi-dose vials Makena only)
Adult and Adolescent pregnant females 16 years and older
250 mg (1 mL) IM once weekly (every 7 days). Begin treatment anytime between 16 weeks and 0 days of pregnancy up to 20 weeks and 6 days of pregnancy. Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first. The effectiveness of hydroxyprogesterone is based on improvement in the proportion of women who delivered at less than 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. LIMITATION OF USE: Hydroxyprogesterone is not intended for use in women with multiple gestations or other risk factors for preterm birth.
Subcutaneous dosage (Makena auto-injector only)
Adult and Adolescent pregnant females 16 years and older
275 mg (1.1 mL) subcutaneously once weekly (every 7 days). Begin treatment anytime between 16 weeks and 0 days of pregnancy up to 20 weeks and 6 days of pregnancy. Continue once weekly until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first. The effectiveness of hydroxyprogesterone is based on improvement in the proportion of women who delivered at less than 37 weeks of gestation. There are no controlled trials demonstrating a direct clinical benefit, such as improvement in neonatal mortality and morbidity. LIMITATION OF USE: Hydroxyprogesterone is not intended for use in women with multiple gestations or other risk factors for preterm birth.
2) For the treatment of inoperable, recurrent, and metastatic endometrial cancer.
1,000 mg or more per week IM (range 1 gram IM once weekly to 1 gram IM once daily). Discontinue when relapse occurs, or after 12 weeks with no objective response. May be used in advanced stage concomitantly with other anticancer therapy (surgery, a radiation, or chemotherapy, or combination of these). Treatment results reported to date have been better in histologically well-differentiated forms of endometrial adenocarcinoma.
3) For the treatment of amenorrhea (primary or secondary) or for dysfunctional uterine bleeding due to hormonal imbalance in the absence of organic pathology.
Adult and Adolescent females
375 mg IM as a single dose, given at any time. Next dose may begin after 4 days of desquamation or, if there is no bleeding, 21 days after the initial single dose. If no response after 4 cycles, discontinue. The number of cycles used and when to use cyclic dosing is dependent on the indication for use and whether estrogen therapy is used concurrently. A suggested cyclic cycle with estrogen is as follows (28-day cycle; repeated every 4 weeks) Day 1 of each cycle: Estradiol Valerate Injection (20 mg IM); then, 2 weeks after Day 1: Hydroxyprogesterone caproate powder 250 mg IM; then Estradiol Valerate (5 mg IM) 4 weeks after Day 1: This is Day 1 of the next cycle. Repeat as indicated. If estrogen deficiency has been prolonged in patients with amenorrhea, menstruation may not occur until estrogen has been given for several months. Discontinue when cyclic therapy no longer required.
To test for endogenous estrogen production (“Medical D and C”).
250 mg IM once; repeat for confirmation at 4 weeks after the first injection. Discontinue after the second dose. Bleeding should occur 7 to 14 days after the injection.
Warning on Hydroxyprogesterone caproate powder
Hydroxyprogesterone caproate powder injection, including compounded products, meet the definition of medical necessity when used to reduce the risk of preterm birth in a female member and ALL of the following criteria are met:
1. The member has a current singleton pregnancy.
2. The member has a documented previous singleton spontaneous preterm birth that occurred at less than 37 weeks gestation due to spontaneous preterm labor or premature rupture of membranes.
3. Member has not had any preterm labor or premature rupture of membranes during the current pregnancy.
4. Treatment is initiated between 16 weeks, 0 days and 20 weeks, 6 days of gestation.
5. Injections are not to be administered more often than weekly until 36 weeks of gestation or time of delivery (whichever occurs first) for a maximum total of no more than 21 injections.
6. Dose does not exceed 250 mg per injection.
The chemical name for Hydroxyprogesterone caproate powder is pregn-4-ene-3,20-dione, 17[(1oxohexyl)oxy]. It has an empirical formula of C27H40O4 and a molecular weight of 428.60. Hydroxyprogesterone caproate powder exists as white to practically white crystals or powder with a melting point of 120°-124°C.
Hydroxyprogesterone caproate powder mechanism of action: the mechanism by which progesterone prevents preterm birth is not well understood, but many pathways are likely involved.Progesterone plays a vital role in regulation of the female reproductive system and is important for successful implantation of the embryo and maintenance of pregnancy. It acts by binding to progesterone receptors in the uterus, ovaries, breasts and in the central nervous system. These receptors exist in 2 isoforms, PR-A and PR-B. Progesterone binding to these receptors ultimately leads to regulation of gene transcription.This results in an anti-inflammatory effect which blunts the proinflammatory state that occurs with initiation of labor, and maintains uterine queiscence by stabilizing progesterone acting on the myometrium.
Pharmacodynamics of Hydroxyprogesterone caproate powder: No specific pharmacodynamic studies have been performed to assess Hydroxyprogesterone caproate powder injections. However, the mechanism of action is likely related to increased interaction between progesterone and progesterone receptors.
Hydroxyprogesterone caproate powder half life is 16 days (±6 days).
Hydroxyprogesterone caproate powder Raw Powder
Min order 10grams.
The inquiry on normal quantity(Within 1kg) can be sent out in 12 hours after payment.
For larger order(Within 1kg)can be sent out in 3 workingdays after payment.
Hydroxyprogesterone caproate powder Marketing
To be provided in the coming future.
How to buy Hydroxyprogesterone caproate powder from AASraw
1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.
PRECAUTION AND DISCLAIMER:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.